Arvid Jungnik
Boehringer Ingelheim (Germany)(DE)
Publications by Year
Research Areas
Diabetes Treatment and Management, Hormonal Regulation and Hypertension, Drug Transport and Resistance Mechanisms, Neuroendocrine Tumor Research Advances, Hormonal and reproductive studies
Most-Cited Works
- → Comparative Pharmacokinetics of Azithromycin in Serum and White Blood Cells of Healthy Subjects Receiving a Single-Dose Extended-Release Regimen versus a 3-Day Immediate-Release Regimen(2006)71 cited
- → Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients(2006)68 cited
- → Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir(2014)60 cited
- → Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906(2022)56 cited
- → Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects(2010)48 cited
- → Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β‐hydroxysteroid dehydrogenase‐1 ( HSD1 ) inhibitor in humans: liver and adipose tissue 11β‐ HSD1 inhibition after acute and multiple administrations over 2 weeks(2016)35 cited
- → Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects(2018)32 cited
- → Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail(2017)31 cited
- → Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers(2010)28 cited
- → Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers(2014)27 cited